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Abstract
Objectives—The Longitudinal Assessment of Manic Symptoms (LAMS) study was designed to
investigate phenomenology and establish predictors of functional outcomes in children with
elevated manic symptoms. The purpose of this series of analyses was to determine whether the
participants demonstrated different trajectories of parent-reported manic and biphasic symptoms
over the first 24 months of follow-up and to describe the clinical characteristics of the trajectories.
Methods—The 707 participants were initially aged 6–12 years and ascertained from outpatient
clinics associated with the four university-affiliated LAMS sites. There were 621 children whose
parents/guardians’ ratings scored ≥ 12 on the Parent General Behavior Inventory–10-item Mania
Form (PGBI-10M) and a matched random sample of 86 children whose parents/guardians’ ratings
scored ≤ 11 on the PGBI-10M. Participants were seen every six months after the baseline and their
parents completed the PGBI-10M at each visit.
Results—For the whole sample, manic symptoms decreased over 24 months (linear effect B =
-1.15, standard error = 0.32, t = -3.66, p < 0.001). Growth Mixture Modeling revealed four unique
trajectories of manic symptoms. Approximately 85% of the cohort belonged to two classes in
which manic symptoms decreased. The remaining ≈ 15% formed two classes (high and rising and
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unstable) characterized by the highest rates of diagnostic conversion to a bipolar disorder (all p-
values < 0.001).
Conclusions—Outcomes are not uniform among children with symptoms of mania or high risk
for mania. A substantial minority of clinically referred children shows unstable or steadily
increasing manic symptoms, and these patterns have distinct clinical correlates.
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Youth receiving mental health services often experience numerous mania-like symptoms (1,
2). Furthermore, although symptoms of mania are, by definition, present in youth suffering
from bipolar disorder, prior data have noted that many youth who experience manic
symptomatology do not suffer from bipolar disorder (3-7). Whether or not a youth has
suffered from a bipolar disorder, it has been noted that elevated symptoms of mania (ESM)
are associated with substantial psychosocial impairments and notable degrees of
psychopathology (7-9).
Despite these initial investigations of children who experience ESM, very little is known
about the phenomenology or symptomatic course of ESM in youth. Data from a pilot study
suggested that the presence of ESM in children with attention-deficit hyperactivity disorder
(ADHD) may be associated with a poorer outcome (9, 10).
The National Institute of Mental Health (NIMH)-supported Longitudinal Assessment of
Manic Symptoms (LAMS) study was designed to better understand the phenomenology and
determinants of outcome (e.g., psychosocial functioning, diagnoses, medications, and
service utilization) in children with ESM. LAMS used an epidemiological approach to
assemble a cohort of 6–12-year-old children at their first outpatient mental health visit at
university-affiliated clinics (11). The LAMS design used a low, sensitive threshold on a
screening instrument for manic symptoms, both to capture a large portion of those already
showing symptoms of bipolarity, but also to include a substantial number of cases without
bipolarity who were also experiencing similar emotional and behavioral dysregulation.
Initial results have confirmed the finding that ESM in clinical mental health settings for
youth are, in fact, common and that the majority of children with ESM indeed do not meet
DSM-IV criteria for a bipolar spectrum disorder at baseline (5). The most common
diagnoses are ADHD, oppositional defiant disorder, conduct disorder, and depression, often
in various combinations (3, 5, 12).
A specific goal of the LAMS study was to examine the course of children’s manic
symptoms over time. To this end, we evaluated whether or not children who participated
demonstrated different trajectories of parent-reported manic and biphasic symptoms over the
first 24 months of follow-up. Based on prior longitudinal investigations of diagnostic status,
combined with the choice of a low threshold of ESM to capture a heterogeneous group of
youths in terms of clinical issues, we anticipated that there would be several distinct
symptom trajectories, including at least one group that showed persistent symptoms of
mania and at least one group that remitted. We also anticipated that a third group might
show intermediate levels of mood symptoms, but whether this would be a stable pattern, or
whether manic symptoms would fluctuate, was an empirical question. We next investigated
what baseline determinants differentiated these distinct trajectories. Finally, we investigated
what factors occur over the span of an initial 24-month observation period that could lead to
categorization into these distinct classes.
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The Institutional Review Boards at each of the four LAMS sites approved all procedures in
the study protocol. Written informed consent and assent were obtained from participants and
their parents/guardians before any study-related procedures were performed.
Study recruitment occurred between December 13, 2005 and December 18, 2008. To be
eligible for screening, children had to: (i) be age 6 through 12 years; (ii) speak English and
have an English-speaking parent/guardian; (iii) be new patients to LAMS outpatient clinics;
and (iv) not live in the same household as another child previously screened. Parents/
guardians of all eligible children were asked to complete the Parent General Behavior
Inventory–10-item Mania Form (PGBI-10M) (13, 14) to screen for ESM and to answer
questions about socio-demographic characteristics. The PGBI-10M comprises items that
both describe hypomanic, manic, and biphasic symptomatology and discriminate bipolar
disorder from other diagnoses in children and adolescents (13). Children whose parents/
guardians’ ratings scored ≥ 12 on the PGBI-10M (ESM+) were invited to participate in the
longitudinal portion of the study. To broaden the variability of the sample, a smaller group
of age-, race-, and socioeconomic status-matched children whose parents/guardians’ ratings
scored ≤ 11 (ESM-) were randomly selected to enroll in the longitudinal study as well. The
rationale for the cut score of 12 on the PGBI-10M, participant ascertainment, and study
design are described in greater detail in Horwitz et al. (11) and Findling et al. (5).
Of the 1,124 children who screened ESM+, 1,111 were eligible (IQ > 70 and no evidence of
autistic disorder) and 621 agreed to participate. In addition, 86 ESM- children enrolled into
the longitudinal study. After the initial screening visit, these 707 children completed a
baseline assessment (5). LAMS participants who continued to be eligible were seen by a
highly trained study interviewer every six months after baseline for a total of up to five visits
over the first 24 months. Interviewer training and inter-rater reliability are described in detail
in Findling et al. (5).
Measures
Demographic characteristics—Parents/guardians provided demographic information,
including child age, sex, race, ethnicity, and health insurance status, as well as family
composition, socioeconomic status, parental education and employment, and medical
history. Appropriate variables (e.g., insurance, employment, and medical history) were
updated at each subsequent study visit.
Psychiatric diagnoses—To assess for current and past psychiatric disorders, children
and their parent/guardian were administered the Schedule for Affective Disorders and
Schizophrenia for School-Age Children-Present and Lifetime Episode (K-SADS-PL) (15)
with additional depression and manic symptom items derived from the Washington
University in St. Louis Kiddie Schedule for Affective Disorders (WASH-U K-SADS) (16,
17). DSM-IV items screening for pervasive developmental disorders were also added to the
K-SADS-PL. The resulting instrument, the K-SADS-PL-W, is a semi-structured interview
that assesses current and lifetime psychiatric diagnoses and the time course of each illness.
The presence/absence of mood disorder diagnoses was assessed at the baseline evaluation
and every six months thereafter. The whole K-SADS-PL-W was repeated annually.
Unmodified DSM-IV diagnostic criteria were used in the LAMS study. The criteria for
bipolar disorder not otherwise specified (BP-NOS) were clarified for the LAMS study to
follow the same criteria used in the Course and Outcome of Bipolar Youth study (COBY)
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(18, 19). BP-NOS was operationalized as follows: (i) elated mood plus two associated
symptoms of mania (e.g., grandiosity, decreased need for sleep, pressured speech, racing
thoughts, increased goal-directed activity, etc.) or irritable mood plus three associated
symptoms of mania; (ii) change in the participant’s level of functioning (increase or
decrease); (iii) symptoms must be present for a total of at least four hours within a 24-hour
period; and (iv) the participant must have had at least four episodes of four hours duration
each or a total of four days of the above-noted symptom intensity in his/her lifetime. All
diagnoses were reviewed and confirmed by a licensed child psychiatrist or psychologist.
Once a child met DSM-IV criteria for any bipolar disorder in the LAMS study, that
diagnosis was always documented as a current diagnosis (although it could be listed as in
partial/full remission).
Medication history—Each child’s parent/guardian provided a complete history of the
child’s past and currently prescribed psychotropic medications during each interview using a
modified version of the Service Assessment for Children and Adolescents (SACA) (20-22).
For simplicity, lithium and anticonvulsants were both classified as mood stabilizers.
Functional assessment—Study interviewers completed the Children’s Global
Assessment Scale (CGAS) (23) to provide a severity rating of participants’ current
impairment, measuring overall functional capacity at home, school, and with peers.
Symptomatic assessment—In addition to administration of the K-SADS-PL-W, which
ascertained presence or absence of manic and depressive symptoms specifically within the
context of a mood episode (i.e., filtered ratings), unfiltered ratings of mood symptoms
(regardless of the presence or absence of a syndromal mood disorder) were also assessed via
both parental self-report and clinical rating scales at each of the five interview time points.
Unfiltered mania ratings were obtained via parental self-report of their child’s functioning
on the PGBI-10M and via direct interview of parents and children using the Young Mania
Rating Scale (YMRS) (24). Unfiltered depression ratings were obtained via direct interview
of parents and children using the Children’s Depression Rating Scale-Revised (CDRS-R)
(25, 26).
At the baseline assessment and every 12 months thereafter, parents completed a 73-item
General Behavior Inventory (GBI) (27) which reflected their own symptoms of mania,
hypomania, and depression. This self-report measure contains two subscales, Hypomanic/
biphasic (mixed, 28 items) and Depressive (46 items). Items are rated from 0 (‘Never or
hardly ever’) to 3 (‘Very often or almost constantly’), with high scores indicating greater
pathology.
Family factors—The Family History Screen (FHS) (28) was obtained at the baseline
assessment to collect information on 15 psychiatric disorders and suicidal behavior in
biological parents, as well as first- and second-degree relatives. For purposes of these
analyses, the participant was considered positive for a family history of elevated mood if one
or both parents endorsed yes for the item questioning whether the parent ever had a period
of ‘feeling extremely happy or high’.
Mental health services use—The SACA was completed with parents to document
mental health services use for inpatient, outpatient and school settings at six month intervals
with detailed data on inpatient and outpatient services (20-22). At each interview, parents/
guardians were asked about the most recent treatment their child had received, to rate how
well the most recent outpatient services matched their child’s needs, and how much their
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child had benefited from the most recent treatment. Data on the type of treatment received
(psychotherapy/medication) were collected as part of the SACA.
Statistical analyses
Analyses proceeded in three stages: (i) determining the overall trend of change in manic
symptoms over time, (ii) identifying separate manic symptom trajectories for overall
symptom scores (such as persistence, recovery, or worsening), and (iii) describing the
correlates of identified trajectories. The first two steps addressed aim 1, the third step
addressed aims 2 and 3 of this study. For the first two steps, the primary dependent variable
was parent-reported manic symptoms (PGBI-10M) measured at baseline, 6 months, 12
months, 18 months, and 24 months. For the third set of analyses, clinical characteristics
(such as age and diagnoses), including baseline and longitudinal measurements (described
below), were used to describe identified manic symptom trajectories.
A common growth model, also known as linear mixed or hierarchical linear model (29-31),
evaluated the overall linear and quadratic trends in manic symptoms across the five time
points. The common growth model enabled us to fully benefit from repeatedly measured
manic symptoms as it tolerates missing observations, a common occurrence in clinical
observational studies. In this procedure, all available cases including the ones with missing
information are included in the analyses. Including every subject who completed at least one
assessment allowed for conservation of power and was also less likely to produce biased
effect estimates. Random effects determined whether individual deviations from the overall
trend were substantial and tested whether empirically estimating separate trends might help
explain heterogeneity of manic symptoms over time.
Next, based on the observation of substantial individual deviations from the overall trend,
growth mixture models (GMM) were estimated. GMM evaluated the number and shape of
separate trajectories and generated individual patient classifications into these trajectories.
The number of separate trajectories was selected based on the Bayesian Information
Criterion (BIC) (32) and the clinical plausibility and interpretability of trajectory classes. An
initial GMM was estimated without baseline covariates. Next, GMMs were estimated with
individual covariates in separate models (including a large number of covariates
simultaneously is impractical for model estimation). Finally, a multi-covariate GMM was
conducted using a subset of baseline factors. This multi-covariate model provided a stringent
test of model stability. Covariates in this model were chosen based on initial hypotheses
about class composition and included: presence of any bipolar spectrum disorder (BPSD)
diagnosis, any adjustment disorder diagnosis, any psychosocial therapy, mood stabilizer use,
and total depression score on the CDRS-R. Initial hypotheses were that some classes would
contain higher proportions of youth with bipolar disorder, some classes would differ in
predominant mood presentation (mania versus depression), and other classes might represent
less functionally impaired classes (where adjustment disorder diagnoses would be over-
represented). Multi-covariate, uni-covariate, and no covariate GMMs all showed highly
similar class solutions. For this reason, results presentation focused on the multi-covariate
model. Interpretation of this model included evaluating relationships between covariates and
the intercept (baseline manic symptom levels), linear slope (changes in manic symptoms
over time), and class membership.
The final multi-covariate GMM included only a subset of potentially interesting baseline
and longitudinal factors. To comprehensively describe baseline characteristics of
empirically-identified classes several additional factors were examined using univariate
ANOVA and chi-square analyses. These included: age, sex, race/ethnicity, YMRS, CGAS,
any family history of elevated mood, parental self-reports of mania and depression,
antipsychotic use, antidepressant use, and stimulant use. Results are presented based on most
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likely class membership, after verifying that the pattern of findings was highly similar using
class probabilities.
Finally, to explore longitudinal differences between classes, we examined the relationship
between class membership, bipolar disorder diagnostic conversion, and utilization of
psychosocial, mood stabilizer, antipsychotic, antidepressant, and stimulant treatment over
the two-year prospective period. Diagnostic progression was moving at any time point at
least one step on a three-step diagnostic continuum from no bipolar diagnosis through BP-
NOS/cyclothymia/bipolar II disorder (BP-II) to bipolar I disorder (BP-I). Diagnostic
progression was classified into one of five categories: (i) no progression (no bipolar disorder
at any time); (ii) no bipolar diagnosis at an earlier time point to any BPSD except BP-I (no
bipolar disorder to BPSD); (iii) no bipolar diagnosis to BP-I (no bipolar disorder to BP-I);
(iv) no bipolar diagnosis to any bipolar disorder (no bipolar disorder to any bipolar
disorder); and (v) BPSD (e.g. BP-NOS/cyclothymia/BP-II) to BP-I (BPSD to BP-I).
Utilization of treatment was defined as the number of six-month intervals in which any form
of psychosocial, mood stabilizer, antipsychotic, antidepressant, or stimulant treatment was
reported.
Mplus (33) was used to estimate the common growth model and GMM analyses. SPSS was
used to describe covariate relationships and longitudinal differences between classes. Class
descriptive analyses were exploratory and, therefore, no a priori multiple comparison
correction was applied to the baseline and 24-month follow-up covariate analyses.
Results
Participant characteristics
Table 1 presents the baseline demographic and clinical characteristics of the cohort.
Previous reports have more fully described the clinically-ascertained LAMS cohort (5, 11).
The data presented herein do not include four individuals who were screened and recruited
into LAMS but ended study between screen and baseline and did not have any baseline or
follow-up PGBI-10M data. The majority of patients had PGBI-10M scores present at a
minimum two of the five time points (86.2%). Data capture remained high even through the
24-month visit (missing: baseline 2.1%, 6-month 24.2%, 12-month 26.4%, 18-month 32.7%,
and 24-month 37.1%). As expected with only four individuals excluded, the remaining
cohort is highly similar to the full LAMS cohort. The participants comprise a
demographically and diagnostically heterogeneous cohort with a wide range of mood
symptom levels and a minority of youth meeting criteria for bipolar diagnoses at baseline.
Missing data analyses for follow-up PGBI-10M data found only one variable distinguishing
those with missing data from other participants: a small trend (largest r = 0.21) for
participants with Medicaid as insurance to have missing data.
Overall manic symptom severity over time
Figure 1 presents the estimated overall mean manic symptom trajectory from the common
growth model overall. Manic symptoms decreased over the two-year period resulting in 4.5
points decline in the PGBI score [p < 0.001, effect size = 0.68 based on standard deviation
(SD) of PGBI at 24 months]. The declines were more rapid for the first year (3.7 points
decline, p < 0.001, effect size = 0.56 based on SD of PGBI at 12 months) than for the rate of
decline during the second year (0.8 points decline, p = 0.001, effect size = 0.12 based on SD
of PGBI at 24 months). Of note, after six months of follow-up, the mean score was below
the threshold (12) used for selection of ESM+ participants; and by 18 months, the mean
score was substantially lower than 12. Individual deviations from the overall trajectory were
often substantial, supporting examination of potentially distinct trajectory shapes.
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Results of GMM analyses identified four unique trajectories of manic symptoms as shown in
Figure 2. The 4-class solution was supported by model fit (BIC: 1-class = 16605; 2-class =
16579; 3-class = 16558; 4-class = 16550; 5-class = 16557), where the difference in BIC
estimates indicated support for the 4-class solution (34). We also monitored the parametric
Bootstrapped Likelihood Ratio Test (BLRT) (35) which preferred a 5-class solution. The 5-
class solution splits one of the 4 classes (C3 in Figure 2) in our 4-class solution into two
smaller trajectory classes (one class starting higher at baseline). The other three classes,
including the ‘unstable (C2)’ class remained unchanged. Based on this observation, we
selected the 4-class solution instead of the 5-class solution that further splits one of the
trajectory classes. The 4-class solution was also preferred based on the clinical plausibility
and interpretability of trajectory classes (further discussed below). The solution was highly
similar across the no covariate, single covariate, and multi-covariate models, indicating good
model stability. Results are presented for the multi-covariate model.
Figure 2 shows that, rather than simply identifying graded differences over time (i.e.,
consistent severity differences), the observed classes represent qualitatively distinct manic
symptom trajectories (different shapes). Two classes comprise smaller proportions of
participants and show a less favorable course. Specifically, Class 1 (High and rising, 8.3%)
begins with high initial symptom levels that continue to increase over time. Class 2
(Unstable, 6.0%) also begins with high levels followed by a sharp decrease, but then
increases back to baseline levels by the 24-month follow-up.
The other two classes accounted for substantially larger proportions of the cohort and
showed more clinically favorable manic symptom trajectories. Class 3 (High and reducing,
38.5%) began with high symptom levels but showed consistent reduction over time. Class 4
(Low and reducing, 47.2%) begins with lower manic symptom levels and also shows
reductions over time. These patterns indicate that a substantial minority of clinically-referred
youth experience ongoing or resurgent manic symptoms, but a larger proportion enjoys
symptom reduction over time.
Differences in participant characteristics between the trajectory classes
Table 2 displays baseline demographic and clinical characteristics as well as diagnostic
progression and treatment utilization at 24-month follow-up, separately by empirically-
derived classes. Tables 3 and 4 present multi-covariate GMM results which represent more
precise estimates of covariate effects (but with a limited number of variables). For
simplicity, the text focuses on descriptive analyses using class membership presented in
Table 2. There were no significant differences between classes for age, sex, race/ethnicity,
any ADHD diagnosis, and any antidepressant use at baseline or throughout the 24-month
study. Features unique to the four classes are described below.
The high and rising class (Class 1) had higher levels of caregiver manic and depressive
symptoms based on the adults’ reports about themselves than the other three classes. Class 1
was more likely than the high and reducing and low and reducing classes to receive both
psychotherapy and antipsychotic medication over the course of the study.
The unstable class (Class 2) at baseline had significantly lower rates of psychosocial therapy
use than the other three classes and less use of mood stabilizers than any class except the
high and rising class. Class 2 was more likely than the high and rising and low and reducing
classes to use stimulants at baseline. Over follow-up, the unstable class was more likely to
receive mood stabilizers and stimulants than the high and reducing and the low and reducing
classes, and was more likely to receive antipsychotics than the low and reducing class. Class
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2 was similar to Class 1 in diagnostic progression over the course of the study and had
higher conversion rates than Classes 3 and 4.
The high and reducing class (Class 3) differed from Classes 1 and 2 by lower rates of mood
stabilizer use at baseline and lower mood stabilizer use across the follow-up period (Class 2
only). Class 3 had higher rates of stimulant use at baseline relative to the high and rising
class (Class 1). Over follow-up, Class 3 was less likely to receive antipsychotic medication
than Class 1 but more likely than Class 4. Class 3 had moderate rates of diagnostic
progression along the bipolar spectrum (lower levels than Classes 1 and 2 but higher than
Class 4).
The low and reducing class (Class 4) differed from Classes 1–3 across almost all baseline
variables. This class had the lowest proportion of bipolar diagnoses at baseline and was least
likely to convert over 24 months. Class 4 had fewer manic symptoms, better functioning,
lower family history burden, highest rate of ESM- participants, and lowest level of
antipsychotic utilization at baseline and across the study.
Diagnostic progression was least common in the low and reducing class (Class 4) compared
to the other three classes [Class 1: high and rising relative risk (RR) = 15.70, 95%
confidence interval (CI): 5.45–46.74; Class 2: unstable RR = 16.82, 95% CI: 5.87–49.75;
Class 3: high and reducing RR = 6.19, 95% CI: 2.42–17.02]. The high and reducing class
(Class 3) was less likely to experience diagnostic progression than the high and rising and
unstable classes. There was a trend toward more progression from no bipolar disorder to BP-
I in the unstable class relative to the high and rising class (z = 1.77, p = 0.077).
Of the 27 baseline and follow-up covariates examined, 21 were significant at p < 0.05. Of
these 21, all survived false discovery rate correction and 15 of 21 survived a conservative
Bonferroni correction (p < 0.0019). Thus, class descriptions across covariates were unlikely
to have been strictly a result of type 1 error.
Discussion
This study evaluated whether LAMS participants demonstrated different trajectories of
parent-reported manic symptoms over the first 24 months of follow-up. This is the first
study to explore longitudinally the progression of manic symptoms in an ascertained cohort
of children and adolescents. Based on prior longitudinal work looking at diagnostic changes,
we anticipated that GMM would identify multiple distinct trajectories. Findings confirmed
the heterogeneity of symptom trajectory. In addition to profiles that followed patterns of
recovery or progression to more severe mood disturbance, the analyses also revealed more
granularity in the trajectories of a large portion of youths in the sample. The four latent
classes of trajectory were unequal in size.
Of note, most LAMS participants belonged to one of two classes of patients that experienced
a reduction in manic symptoms over time. The improvement in this large majority of
patients is reassuring, reinforcing the point that what may appear to be manic symptoms at a
given time point may reflect a variety of underlying diagnoses, and can follow several
different longitudinal trajectories. Families are often concerned about prognosis given
reports of poor outcomes and concerns about children with manic symptoms or bipolar
disorder (7-9); findings indicate that there are likely to be multiple causes and outcomes for
what many appear to be similar initial presentations (18, 36). However, approximately 15%
of the sample was in one of two classes of patients that either experienced an increase in
manic symptoms or an unstable pattern of symptoms over time, with high rates of diagnostic
progression.
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In addition to these global observations, interesting between-class differences were also
found. Not surprisingly, the low and reducing class (Class 4) differs at baseline from the
other three classes. More specifically, Class 4 demonstrated the fewest bipolar diagnoses,
both at baseline and over the 24-months of the study, the highest functioning, and the lowest
rate of antipsychotic use at baseline and throughout the study. These results are consistent
with the fact that most of the ESM- recruits were in Class 4 and would not have been
predicted to manifest a bipolar diagnosis. They are also internally consistent with a previous
LAMS report that antipsychotic use is associated with more severe psychopathology and
dysfunction (37).
By way of contrast, the high and rising class (Class 1) has the highest rates of parental self-
reported symptoms of mania and depression. As this association is not necessarily reflective
of causal relationships, it is possible that this association is simply a reflection of higher
degrees of global symptomatic reporting. Additionally, it is possible that reports of child
behavior problems and psychopathology are inflated by parents with mood symptoms, a
phenomenon that has been explored in maternal depression (38-40). However, the
possibility that higher degrees of parental self-reported affective symptoms may be
associated with worse outcomes in their children is a consideration that seems plausible both
genetically and environmentally, thus deserving further evaluation.
The unstable class (Class 2) has the lowest amount of psychosocial interventions and the
highest rate of stimulant treatment, both at baseline and when considering all follow-up time
points. As this result was surprising to us, these findings may simply reflect type I error.
As outlined in previous LAMS reports (5, 11, 37), this study is primarily limited by the
inability to generalize these findings to the general population of children due to the fact that
participants were recruited from clinical settings. While the data presented herein were
collected from 703 LAMS participants, the data do not reflect a PGBI-10M score for each of
these participants at each of the five possible time points. Additionally, while a large portion
of the data provided by the LAMS cohort are generated by carefully trained, reliable
interviewers (5), many of the findings presented in this paper are based on data from parent
report. Finally, because this was the first study to use these statistical methods on
prospective longitudinal data for manic symptoms, we did not have strong a priori
hypotheses about the number of classes or their trajectories. Our findings were based on best
practices of current statistical methods and are consonant with what we would expect based
on studies of diagnostic change. They also provide a strong foundation for future prediction
and replication in independent samples.
Despite its limitations, this study found that elevated manic symptoms are heterogeneous
and are characterized by distinct courses. The data indicate that what may appear to be
manic symptoms can be associated with a variety of diagnoses and with multiple distinct
trajectories over time. Findings complement recent work in adults with bipolar disorder that
also empirically identified distinct classes based on summaries of patterns in mood
symptoms. Our data may provide the ability to prognosticate outcome for children with
elevated manic symptoms at the time of their initial assessment. Further, if the
approximately 15% of children who do not experience a reduction in manic
symptomatology over time can be identified at the start of treatment or at least early in the
course of treatment, they may then be specifically targeted for more intensive therapeutic
attention.
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A unique finding from this study is that the presence of four distinct classes demonstrates
that outcomes are not uniform among youth with symptoms of mania. Most LAMS
participants did well in respect to manic symptoms over time, compared to youth with
bipolar disorder, who frequently struggle over the long term. While this study found several
associations between manic symptom trajectory and clinical characteristics, subsequent
research will be needed to determine whether these associations are indeed reflective of
causal relationships and how much long-term prognostic value they have.
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Estimated overall growth trajectory of Parent General Behavior Inventory–10-item Mania
Form (PGBI-10M).
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Estimated Parent General Behavior Inventory–10-item Mania Form (PGBI-10M) growth
trajectory classes in the presence of covariates (N = 703).
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Table 1
Longitudinal Assessment of Manic Symptoms cohort baseline demographic and clinical characteristics (N =
703)
Baseline sample characteristics
Age, years, mean (SD) 9.4 (1.9)
Male, n (%) 477 (67.9)
White, non-Hispanic, n (%) 437 (67.2)
Health insurance, n (%)
 Medicaid 366 (52.1)
 Private 283 (40.2)
 Private and Medicaid 44 (6.3)
 Self-pay 10 (1.4)
Living with both biological parents, n (%) 223 (31.7)
History of psychiatric hospitalizations, n (%) 64 (9.1)
Any bipolar diagnosis, n (%) 162 (23.0)
 BP-I 71 (10.1)
 BP-II 3 (0.4)
 BP-NOS 77 (11.0)
 Cyclothymia 11 (1.6)
Any adjustment disorder diagnosis, n (%) 13 (1.8)
Mood symptom and functional measures, mean (SD)
 PGBI-10M 12.9 (7.2)
 YMRS 16.8 (9.2)
 CDRS-R 34.8 (10.7)
 CGAS 54.6 (10.3)
BP-I = bipolar I disorder; BP-II = bipolar II disorder; BP-NOS = bipolar disorder not otherwise specified; PGBI-10M = Parent General Behavior
Inventory–10 item mania form; YMRS = Young Mania Rating Scale; CDRS-R = Children’s Depression Rating Scale–Revised; CGAS =
Children’s Global Assessment Scale.
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Table 3
Four-class growth mixture analysis: mixed effects linear regression of baseline covariates and longitudinal P-
GBI development within trajectory class
Parameter Estimate SE p-value
Random intercept (initial P-GBI) regressed on covariates
Intercept 12.996 1.359 0.000
Any bipolar diagnosis 1.738 0.714 0.015
Adjustment disorder diagnosis -2.548 1.266 0.044
Any therapy -0.127 0.293 0.666
CDRS-R total score 0.077 0.025 0.002
Random intercept residual variance 12.744 2.326 0.000
Random linear slope (linear decline) regressed on covariates
Intercept -5.641 1.519 0.000
Any bipolar diagnosis -1.729 0.686 0.012
Adjustment disorder diagnosis -0.252 1.016 0.804
Any therapy -0.647 0.230 0.005
CDRS-R total score -0.017 0.021 0.426
Random slope residual variance 0.597 0.189 0.002
Random intercept and slope covariance -2.579 0.602 0.000
Quadratic slope (deceleration or acceleration of change) regressed on covariates
Intercept 1.536 0.381 0.000
Any bipolar diagnosis 0.325 0.163 0.045
Adjustment disorder diagnosis 0.332 0.210 0.114
Any therapy 0.149 0.054 0.006
CDRS-R total score 0.001 0.005 0.837
Residual variance Fixed at 0 – –
SE = standard error; P-GBI = Parent General Behavior Inventory–10-item Mania Form (PGBI-10M); CDRS-R = Children’s Depression Rating
Scale–Revised.
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Table 4
Four-class growth mixture analysis: multinomial logit regression of baseline covariates and trajectory class
membership
Parameter Estimate SE p-value
C1 versus C4
Logit intercept -3.993 0.672 0.000
Any bipolar diagnosis 2.485 0.575 0.000
Mood stabilizer -0.135 0.659 0.838
Any therapy 0.504 0.172 0.003
CDRS-R total score 0.047 0.015 0.002
C2 versus C4
Logit intercept -1.963 0.739 0.008
Any bipolar diagnosis 1.434 0.717 0.046
Mood stabilizer 0.966 0.618 0.118
Any therapy -0.924 0.538 0.086
CDRS-R total score 0.014 0.019 0.464
C3 versus C4
Logit intercept -1.791 0.447 0.000
Any bipolar diagnosis 2.169 0.495 0.000
Mood stabilizer -1.014 0.677 0.134
Any therapy 0.353 0.159 0.027
CDRS-R total score 0.029 0.012 0.019
C1 versus C2
Any bipolar diagnosis 1.051 0.779 0.177
Mood stabilizer -1.101 0.835 0.187
Any therapy 1.428 0.559 0.011
CDRS-R total score 0.033 0.020 0.108
C2 versus C3
Any bipolar diagnosis -0.735 0.787 0.351
Mood stabilizer 1.980 0.847 0.019
Any therapy -1.277 0.576 0.027
CDRS-R total score -0.015 0.019 0.441
SE = standard error; CDRS-R = Children’s Depression Rating Scale–Revised.
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